Subcutaneous application of gentamicin collagen implants as prophylaxis of surgical site infections in laparoscopic colorectal surgery: A randomized, double-blinded, 3-armed trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00006239

Enrollment

297

Registered

2014-06-12

Start date

2008-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T81.4

Interventions

Group 1: Subcutaneous application of a gentamicin collagen sponge (GCS) (Gentacoll resorb®, Resorba Medical GmbH, Nürnberg, Germany) of 6,25 cm2 containing 17,5 mg equine collagen and 12,5 mg gentamic

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All adult patients scheduled for an elective laparoscopic resection

Exclusion criteria

Exclusion criteria: known allergic reaction to gentamicin or animal collagen, refusal to participate, expected incompliance or intraoperative conversion to open surgery

Design outcomes

Primary

Measure	Time frame
Surgical Site Infection (according definition of CDC) in the first 28 days after surgery, visite by investigator	—

Secondary

Measure	Time frame
incidence of surgical or general complications, the length of hospitalization and the incidence of incisional hernias during study period, check of patient file	—

Countries

Germany

Contacts

Public ContactJulius Pochhammer

Klinik für Allgemein-, Viszeral- und ThoraxchirurgieMarienhospital Stuttgart

viszeral-allgemeinchirurgie@vinzenz.de0711/6489-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026